NCT02993159View on ClinicalTrials.gov

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

March 30, 2021

Study Completion Date

January 24, 2022

Conditions
Ductal Breast Carcinoma In SituEstrogen Receptor Positive
Interventions
DRUG

Afimoxifene

Applied to the breast

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Given PO

OTHER

Placebo

Applied to the breast

DRUG

Tamoxifen Citrate

Given PO

Trial Locations (6)

10065

Memorial Sloan-Kettering Cancer Center, New York

27710

Duke University Medical Center, Durham

41017

Saint Elizabeth Medical Center South, Edgewood

44106

Cleveland Clinic, Cleveland

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

BHR Pharma, LLC
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

BHR Pharma, LLC

INDUSTRY

lead

Northwestern University

OTHER